Cholangiocarcinoma News

Curative Surgery After 3-Drug Chemotherapy Regimen Extends Survival in Patients with Locally Advanced CCA

Web Exclusives — March 22, 2022

The current standard first-line therapy for advanced cholangiocarcinoma (CCA) is the chemotherapy combination of gemcitabine plus cisplatin; only about 40% of patients are amenable to surgery. The objective of this retrospective study was to evaluate the clinical feasibility of the triplet chemotherapy regimen of nab-paclitaxel plus gemcitabine and cisplatin as first-line therapy in patients with locally advanced CCA.

The results were presented by Sung Hoon Choi, BA, CHA University, Seongnam-Si, South Korea, at the 2022 ASCO GI Cancers Symposium.

This retrospective analysis was based on a chart review of patients with locally advanced CCA who received the triplet regimen of nab-paclitaxel plus gemcitabine and cisplatin between October 2019 and December 2020. The feasibility of resection after induction chemotherapy was evaluated by a multidisciplinary team.

The investigators assessed the perioperative outcomes and pathologic results of surgical resection after induction chemotherapy.

Of the 85 patients in this study, 46 (54.1%) patients had measurable lesions, 24 patients had a diagnosis of intrahepatic CCA, 37 had extrahepatic/perihilar CCA, and 24 had extrahepatic/distal CCA.

In the overall population, after induction chemotherapy, the objective response rate in patients with measurable disease was 51.1%, and the disease control rate was 85.1%. Of the 85 patients in the study, 52 (61.2%) patients had resectable tumors.

Among all the patients in this study, 48 (56.5%) patients underwent subsequent curative surgery. In the subset of patients who underwent surgery, 6 (12.5%) achieved complete remissions (all in extrahepatic CCA); R0 resection was achieved in 43 (89.6%) patients.

The overall survival (OS) rates were significantly higher among patients who had induction chemotherapy followed by surgery compared with those who received chemotherapy alone, with a 12-month OS of 94.9% versus 72.6%, respectively (P = .009).

These data support the clinical feasibility of induction chemotherapy with nab-paclitaxel plus gemcitabine and cisplatin before curative surgery in patients with locally advanced CCA.

Source

Choi SH, Kang B, Cheon J, et al. Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma. Abstract 387.

Related Items

CCA Summit Live from ASCO GI 2023
By Stacey Stein, MD
Videos
On January 20, 2023, I presented an overview of key abstracts on cholangiocarcinoma (CCA) presented at the 2023 annual American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2023). In addition, I provided my perspective on the impact of the data on the management of patients with CCA.
Erdafitinib in Asian Patients with Advanced CCA and FGFR Alterations: Updated Analysis
March 2022, Vol 3, No 1
The ongoing open-label, multicenter, phase 2a LUC2001 study is investigating the efficacy and safety of the FGFR inhibitor erdafitinib in a molecularly defined subset of Asian patients with advanced cholangiocarcinoma (CCA) harboring FGFR alterations whose disease progressed after ≥1 previous systemic therapies.
Sitravatinib plus Tislelizumab for Advanced Biliary Tract Cancer in Patients Whose Disease Did Not Respond to at Least 1 Systemic Therapy
March 2022, Vol 3, No 1
Given that monotherapy with immune checkpoint inhibitors, including the PD-1 inhibitor tislelizumab, has a modest effect in advanced biliary tract cancers, several combination strategies to improve the antitumor activity of immune checkpoint inhibitors are being explored.
Systemic Modified FOLFIRINOX Followed by Concurrent Floxuridine and Systemic Modified FOLFIRI in Patients with Unresectable CCA: The HELIX-ICC Study
March 2022, Vol 3, No 1
The majority of patients with intrahepatic cholangiocarcinoma (CCA) present with advanced liver disease and are not candidates for curative resection. The current standard of care for patients with unresectable intrahepatic CCA is palliative chemotherapy with gemcitabine plus cisplatin.
Tucatinib plus Trastuzumab in Patients with Biliary Tract Cancer and HER2 Expression: Phase 2 Basket Study
March 2022, Vol 3, No 1
Biliary tract cancers have dismal prognosis, and the treatment options are limited. Up to 15% of patients with biliary tract cancer have HER2-positive disease. Tucatinib is a highly selective HER2-­directed tyrosine kinase inhibitor.
Quality-of-Life Trends Associated with Ivosidenib in Patients with CCA and IDH1 Mutation in the ClarIDHy Study
March 2022, Vol 3, No 1
Ivosidenib is a first-in-class inhibitor of IDH1 mutation that is indicated for the treatment of previously treated, locally advanced or metastatic cholangiocarcinoma (CCA) and IDH1 mutation. This indication was approved based on the results of the phase 3 ClarIDHy clinical trial, which demonstrated significant improvement in progression-free survival with ivosidenib compared with placebo in patients with previously treated, unresectable or metastatic CCA harboring IDH1 mutations.
Pembrolizumab plus Granulocyte Macrophage Colony-Stimulating Factor in Patients with Advanced Biliary Tract Cancer
March 2022, Vol 3, No 1
Immune checkpoint inhibitors used as monotherapy have dem­onstrated only modest activity in unselected patients with advanced biliary tract cancers, highlighting the need for novel strategies to improve patient outcomes. Granulocyte macrophage colony-stimulating factors (GM-CSF) show immunomodulatory effects and may therefore potentiate the activity of immune checkpoint inhibitors.
Varlitinib plus Gemcitabine and Cisplatin for First-Line Therapy in Patients with Advanced Biliary Tract Cancers
March 2022, Vol 3, No 1
The current standard of care for the first-line treatment of patients with advanced biliary tract cancer is chemotherapy combination of gemcitabine plus cisplatin; however, this regimen yields only modest responses, underscoring the need for novel, more active treatments. Human epidermal growth factor receptor (HER) tyrosine kinases are often overexpressed in patients with biliary tract cancers.
Second-Line Chemoimmunotherapy in Patients with Advanced Biliary Tract Cancers: The BilT-03 Study
March 2022, Vol 3, No 1
The multicenter, single-arm, phase 1b/2 BilT-03 study evaluated the benefit of a chemoimmunotherapy regimen that combines the 3-drug chemotherapy regimen of liposomal irinotecan, 5-fluorouracil (5-FU), and leucovorin, plus the PD-1 monoclonal antibody nivolumab, as second-line therapy in patients with advanced biliary tract cancers. The results were presented by Vaibhav Sahai, MBBS, MS, University of Michigan, Ann Arbor, at the 2022 ASCO GI Cancers Symposium.
Central Hepatobiliary Adverse Events in Patients with Liver Malignancies Undergoing Stereotactic Body Radiotherapy
March 2022, Vol 3, No 1
Stereotactic body radiotherapy (SBRT) is increasingly being used for the treatment of patients with primary or metastatic liver cancer. A single-institution study was conducted to assess the incidence of central hepatobiliary adverse events (AEs) in patients with liver malignancies who were treated with SBRT, and to evaluate the relation with planned dosimetry to define predictors to minimize AEs. The results were presented by Nitika Thawani, Dignity Health Cancer Institute, Phoenix, AZ, at the 2022 ASCO GI Cancers Symposium.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: